Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT for Valeant Pharmaceuticals International

Related VRX
Are There Any Winners Left In The Biotech Space?
Zoetis Inc. Spikes Briefly On Remarks From Sanofi CEO
Energy Sector Seen as Biggest Risk to Deal Flow in 2015 (Fox Business)

In a report published earlier today, Jefferies & Company, Inc. reiterated its Buy rating for Valeant Pharmaceuticals International, Inc. (NYSE: VRX), but lowered its price target from $75.00 to $63.00.

Jefferies went on to say “After what we viewed as an excellent analyst day yesterday, VRX remains controversial ... yet an excellent investment -- especially after yesterday's weakness. For a company with >20% exposure in Europe, to actually reaffirm the UPPER end of its EPS guidance is a testament to the strength and durability of its business model. We now lower our PT for a more realistic market.”

Valeant Pharmaceuticals International, Inc. closed yesterday at $45.23.

Latest Ratings for VRX

DateFirmActionFromTo
Oct 2014Cantor FitzgeraldMaintainsBuy
Oct 2014JefferiesMaintainsBuy
Aug 2014Cantor FitzgeraldMaintainsBuy

View More Analyst Ratings for VRX
View the Latest Analyst Ratings

Posted-In: Jefferies & Company Inc.Analyst Color Price Target Reiteration Analyst Ratings

 

Related Articles (VRX)

Around the Web, We're Loving...

Get Benzinga's Newsletters